Home > Oncology > ESMO 2022 > OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant

OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant

Presented By
Dr Mathew Goetz, Mayo Clinic Rochester, MN, USA
Conference
ESMO 2022
Trial
Phase 3, MONARCH 3
Results from the second interim analysis of MONARCH 3 show that overall survival (OS) is numerically longer with abemaciclib plus a non-steroidal aromatase inhibitor (NSAI) versus placebo plus a NSAI in the first-line setting, in post-menopausal patients with HR-positive/HER2-negative advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that -in the MONARCH 2 trial (NCT02107703), in combination with fulvestrant- demonstrated significant OS benefit in pre- and post-menopausal patients with HR-positive/HER2-negative advanced breast cancer who had disease progression on prior endocrine therapy [1]. The phase 3 MONARCH 3 trial (NCT02246621) investigates the efficacy and safety of abemaciclib plus a NSAI in the first-line setting in post-m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on